Data analysis experts at the PROOF (Prevention of Organ Failure) Centre played a central role in a new study that found a readily available antiviral drug could be used to treat COVID-19.

The PROOF team analyzed data from 77 patients in Wuhan, China who were hospitalized with COVID-19 in January and February of this year.

“Our team played key roles in quality assurance, exploratory and statistical analyses, in order to identify cellular and molecular signals associated with the clinical course of disease, and with responses to different treatments,” said Dr. Scott Tebbutt, who was recently named the new CEO of PROOF, taking over the role from founder Dr. Bruce McManus.

Read the full story on The Daily Scan